lapatinib
information and resources from the National Cancer Institute
NCI Thesaurus | lapatinib
A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.NCI Thesaurus | lapatinib
A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
|
|
|
|
news articles
Two Promising Drugs For Breast Cancer - Raloxifene And Lapatinib Mar 24, 2006
Medical News Today (press release), ...tamoxifen). An example of a molecule causing much interest in breast cancer treatment is lapatinib, which administered orally. It ...
Two New Cancer Drugs Discovered Mar 28, 2006
Medical News Today (press release), Delegates at the European Breast Cancer Conference (EBCC-5) were given two examples of promising new drugs to watch in the future - raloxifene and lapatinib. ...
Doctors urge brain scans for cancer patients Mar 14, 2006
BurlingtonFreePress.com, Studies are under way to see if an experimental drug called lapatinib, made by GlaxoSmithKline, can treat breast cancer that spreads to the brain. ...
(PRN) GlaxoSmithKline Initiates Trial Of Tykerb (Lapatinib) in ... Dec 9, 2005
Houston Chronicle, GlaxoSmithKline (GSK) has announced the initiation of a global multicenter Phase II trial (known as EGF105084) to evaluate Tykerb (lapatinib) for the treatment ...
GlaxoSmithKline initiates trial of Tykerb (lapatinib) in patients ... Dec 9, 2005
WebWire (press release), 2005– GlaxoSmithKline (GSK) has announced the initiation of a global multicenter Phase II trial (known as EGF105084) to evaluate Tykerb (lapatinib) for the ...
Future Of Medicine In A Modern World Dec 20, 2005
News Letter, Chief among the company's innovations already is lapatinib which could soon rival Roche's Herceptin - the best available treatment for breast cancer. ...
GlaxoSmithKline cancer drug threatens Herceptin market Dec 9, 2005
Nature.com (subscription), GlaxoSmithKline (GSK) has been ramping up efforts to bring small-molecule GW 572016 (lapatinib), the only dual-action tyrosine kinase inhibitor in phase 3 ...
Movers: Bombardier posts loss on job cuts in Europe Dec 1, 2005
International Herald Tribune, ...have four potential blockbuster drugs in development in 2006, and planned to seek approval from US regulators to sell the breast cancer drug Lapatinib, to be ...
Investigational Treatment Shows Promise in Metastatic Breast ... Nov 21, 2005
Newswise (press release) Newswise — Encouraging response rates have been achieved in women with advanced breast cancer treated with the investigational drug lapatinib, according to a ...
Hope for Metastatic Breast Cancer Nov 27, 2005
Ivanhoe, According to a study published in Core Evidence, lapatinib shows a response in a group of women with metastatic breast cancer, a disease doctors say offers a ...
GSK in drive for new cancer drugs Nov 30, 2005
Times Online, The latest drugs to progress to phase-three trials are Tykerb, until recently known as Lapatinib, a once-daily pill for breast cancer that could ultimately ...
Glaxo, Oxford University to develop cancer drugs in India Nov 19, 2005
Webindia123, The company plans to open six centres in India to test products such as Lapatinib for breast cancer and Cervarix, its potential blockbuster vaccine against ...
GlaxoSmithKline to cast clinical research net in India beyond ... Nov 21, 2005
Myiris.com, The cancer trials are expected to commence in January 2006 and one of the molecules that GSK is researching is Lapatinib, a dual action treatment being ...
GlaxoSmithKline "buy" Dec 1, 2005
New Ratings In its efforts to position Lapatinib, GlaxoSmithKline has indicated that it would start up to five new studies for the drug in adjuvant, first and second line ...
Drug shows promise against breast cancer Nov 21, 2005
United Press International A report in the journal Core Evidence says between 10 percent and 38 percent of women with metastatic breast cancer responded to treatment with lapatinib. ...
(PRN) - MTS Announces Subscriber Growth Numbers for November 2005 ... Dec 9, 2005
Bolsamania.com, True Health to Focus on Medical Equipment Sales ... [+. PRN) - GlaxoSmithKline Initiates Trial Of Tykerb (Lapatinib) in Patients With ErbB2- Overexpressing ...
Glaxo starts development of new drugs and new test centers in ... Nov 18, 2005
India Daily, Glaxo plans to open six centres on the Indian subcontinent to test promising products such as Lapatinib for breast cancer and Cervarixits, its potential ...
Glaxo sees 4 cancer drugs in final trials in 2006 Nov 30, 2005
Reuters Europe's biggest drug maker said Tykerb, formerly known as lapatinib, eltrombopag, casopitant and pazopanib all held promise for fighting tumours and helping ...
Glaxo sees 4 cancer drugs in final trials Nov 30, 2005
Reuters.uk, Europe's biggest drug maker said the four drugs -- Tykerb, formerly known as lapatinib, eltrombopag, casopitant and pazopanib -- all held promise for fighting ...
GSK to have four cancer drugs in late stage trials next year Nov 30, 2005
Forbes In an update on its oncology and supportive care portfolio, Europe's biggest drug maker said Tykerb, previously called lapatinib, has demonstrated promise as ...
Glaxo to put 4 new cancer drugs into final trials Nov 30, 2005
Reuters Tykerb, formerly known as lapatinib, eltrombopag, casopitant and pazopanib -- all held promise for fighting tumours or helping patients overcome the side ...
London shares under pressure midmorning on weak energy and pharma ... Nov 30, 2005
Forbes Analysts say that among the key drugs to look out for are '115 (a test for low blood platelet levels) and Lapatinib (breast cancer treatment). ...
Glaxo to showcase cancer drugs Nov 25, 2005
ABC News A lot of time is also expected to be devoted to lapatinib, a drug initially being developed for breast cancer but which could have applications in a wide range ...
Glaxo boss set to give R&D extra billions Nov 26, 2005
The Sunday Times, Highlights are likely to include Cervarix, a vaccine for cervical cancer, Lapatinib, a treatment for breast cancer, and Eltrombopag, which is being tested on ...
GlaxoSmithKline Presents Rapidly Expanding Pipeline of Oncology ... Nov 30, 2005
Finanzen.net, Four NCEs highlighted in this seminar are expected to be in phase III development in 2006: Tykerb (lapatinib), eltrombopag ('115), casopitant ('769), and ...
Glaxo Touts Progress on Seven New Drugs Nov 30, 2005
Smartmoney.com Four drugs to reach the stage next year include: Tykerb, also known as lapatinib, for the treatment of breast cancer; eltrombopag to treat low-blood platelet ...
Glaxo lines up new cancer drug trials Nov 30, 2005
Life Style Extra, The drug titan said targeted oral therapy Tykerb, formerly lapatinib, has the potential to become an essential component in the treatment of breast cancer. ...
Glaxo makes big foray into cancer market Nov 30, 2005
United Press International ...treatment and supportive care. The new compounds are Tykerb (lapatinib), eltrombopag, casopitant and pazopanib. Tykerb is being ...
GlaxoSmithKline to put four cancer drugs in late-stage trials in ... Nov 30, 2005
New Ratings ...drug maker, said that the four new cancer drugs to enter into final-stage clinical trials in 2006 would be Tykerb (formerly known as lapatinib) for breast ...
GlaxoSmithKline Key Data Eyed At Update Weds Nov 28, 2005
New Ratings The company should also provide detailed phase II data for breast cancer drug lapatinib, including an update on filing with regulators. ...
UBS Bullish On GlaxoSmithKline; Keeps Buy Nov 28, 2005
New Ratings Expects it to discuss '115 (TPO for thrombocytopaenia), lapatinib (breast cancer), pazopanib ('034, VEGFR inhibitor in renal cancer) and the NK1 program ...
GSK to showcase '$2.8bn' cancer drug Nov 26, 2005
Telegraph.co.uk, The company is also expected to give details of other potential cancer drugs, including lapatinib, a medicine initially developed for breast cancer but which ...
Last Week’s News Nov 21, 2005
DCCcafe.com, Entereg (from GlaxoSmithKline and Adolor), diabetes drug Exenatide (from Eli-Lily, Amylin, and Alkermes), and breast cancer treatment Lapatinib (also from ...
|
|
